Followers
0
Following
0
Blog Posts
0
Threads
5,968
Blogs
Threads
Portfolio
Follower
Following
2021-01-01 12:10 | Report Abuse
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Do you feel very very strange !!!...............
Why expert only opt for Hartalega....but not Supermax !!!!!!!!!!
--------------------------------------------------------------------------------------------
The 11 stocks experts say you should own in 2021
(theedgemarkets.com / January 01, 2021 10:00 am +08)
The world went into real uncharted territories in 2020, starting with a pandemic no one had foreseen, and one the world had not experienced in decades. And while the subsequent slump in the equity markets was expected, the wild surge upwards as bulls dominated — including in Bursa Malaysia — was rather not, especially with the yet-to-dissipate shadows cast by the coronavirus.
Moving forward, the availability of vaccines raises optimism of a better year ahead.
The Edge contacted fund managers and analysts to tap their expertise in picking the stocks for 2021. Below is the list of stocks they highlighted:
Hartalega Holdings Bhd
If you still believe in the great earnings growth story in the rubber glove industry despite the availability of the Covid-19 vaccine, Hartalega Holdings Bhd could be a choice to buy on strength given that the stock has sagged almost 43% from its peak of RM21.16, according to Maybank IB.
Hartalega, the world’s largest nitrile glove maker, is one of Maybank IB’s top picks. It is projecting 580% growth on earnings per share in FY21 and 100% in FY22.
Hartalega stands out among the glove stocks, according to Maybank IB, due to lower oversupply risk in the nitrile space considering the limited supply of raw material, namely nitrile-butadiene rubber (NBR).
The anticipated continued robust growth has in turn made Hartalega appealing in terms of PER. Maybank IB noted that Hartalega's PER valuation is undemanding at nine times in 2021 and 12 times in 2022.
Furthermore, investment analysts believe that Hartalega may have room to raise its average selling prices to catch up with others in the industry that have already upped their selling prices substantially.
Any rebound might not be across the board in the coming year as the glove mania seems to be cooling off in the fourth quarter of 2020. Hence, stock selection is important moving forward.
## https://www.theedgemarkets.com/article/stock-picks
2021-01-01 12:10 | Report Abuse
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Do you feel very very strange !!!...............
Why expert only opt for Hartalega....but not Top Glove !!!!!!!!!!
--------------------------------------------------------------------------------------------
The 11 stocks experts say you should own in 2021
(theedgemarkets.com / January 01, 2021 10:00 am +08)
The world went into real uncharted territories in 2020, starting with a pandemic no one had foreseen, and one the world had not experienced in decades. And while the subsequent slump in the equity markets was expected, the wild surge upwards as bulls dominated — including in Bursa Malaysia — was rather not, especially with the yet-to-dissipate shadows cast by the coronavirus.
Moving forward, the availability of vaccines raises optimism of a better year ahead.
The Edge contacted fund managers and analysts to tap their expertise in picking the stocks for 2021. Below is the list of stocks they highlighted:
Hartalega Holdings Bhd
If you still believe in the great earnings growth story in the rubber glove industry despite the availability of the Covid-19 vaccine, Hartalega Holdings Bhd could be a choice to buy on strength given that the stock has sagged almost 43% from its peak of RM21.16, according to Maybank IB.
Hartalega, the world’s largest nitrile glove maker, is one of Maybank IB’s top picks. It is projecting 580% growth on earnings per share in FY21 and 100% in FY22.
Hartalega stands out among the glove stocks, according to Maybank IB, due to lower oversupply risk in the nitrile space considering the limited supply of raw material, namely nitrile-butadiene rubber (NBR).
The anticipated continued robust growth has in turn made Hartalega appealing in terms of PER. Maybank IB noted that Hartalega's PER valuation is undemanding at nine times in 2021 and 12 times in 2022.
Furthermore, investment analysts believe that Hartalega may have room to raise its average selling prices to catch up with others in the industry that have already upped their selling prices substantially.
Any rebound might not be across the board in the coming year as the glove mania seems to be cooling off in the fourth quarter of 2020. Hence, stock selection is important moving forward.
## https://www.theedgemarkets.com/article/stock-picks
2021-01-01 11:42 | Report Abuse
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Keyman188 very scared to become warrior or hero...
Keyman188 no harm better listen more to Professionals & Expertise to avoid become shark & crocodile victim...
Keyman188 not the professional or expertise...Let the expertise give more advise to the market...
为什么想投资科技股就必须关注美国大选最终结果?马股橱窗粉饰之后会有调整吗? - 陈剑
##https://klse.i3investor.com/blogs/kianweiaritcles/2020-12-26-story-h1538398268.jsp
业绩这么好为何股价涨不动?近期手套股业绩和股价走势背离最完整讲解!- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-20-story-h1536526427.jsp
新冠疫苗面世后,股市里的聪明钱会去哪里?对手套板块有多大影响?- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-14-story-h1536429185.jsp
-----------------------------------------------------------------------------------------------------------------------
That's reason why some investment banks (IB) had started to revise glove sector outlook.........
Hereby to enclose the latest glove preview & outlook by IB...
Macquarie downgrades Top Glove to 'underperform', halves target price as earnings could normalise in 2H21
(theedgemarkets.com / September 10, 2020 17:36 pm +08)
##https://www.theedgemarkets.com/article/macquarie-downgrades-top-glove-underperform-halves-target-price-earnings-could-normalise
JP Morgan pegs these glove makers' fair value at up to half their market price, says supernormal cycle is over
(theedgemarkets.com / December 12, 2020 00:16 am +08)
##https://www.theedgemarkets.com/article/jp-morgan-pegs-these-glove-makers-fair-value-half-their-market-price-says-supernormal-cycle
PublicInvest Research downgrades Top Glove to 'neutral' on ESG concerns
(theedgemarkets.com / December 18, 2020 10:38 am +08)
##https://www.theedgemarkets.com/article/publicinvest-research-downgrades-top-glove-neutral-esg-concerns
Revision :-
Macquarie - TP : 5.45
JP Morgan - TP : 3.50
PB IB - TP : 7.30
-----------------------------------------------------------------------------------------------------------------------
Keyman188 comment is only for those need to heard & perceive...
Save your hard earned money to avoid fighting with Big Funds...
Sometime need to follow the "wind" where to come...where to blow....
2021-01-01 11:42 | Report Abuse
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Keyman188 very scared to become warrior or hero...
Keyman188 no harm better listen more to Professionals & Expertise to avoid become shark & crocodile victim...
Keyman188 not the professional or expertise...Let the expertise give more advise to the market...
为什么想投资科技股就必须关注美国大选最终结果?马股橱窗粉饰之后会有调整吗? - 陈剑
##https://klse.i3investor.com/blogs/kianweiaritcles/2020-12-26-story-h1538398268.jsp
业绩这么好为何股价涨不动?近期手套股业绩和股价走势背离最完整讲解!- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-20-story-h1536526427.jsp
新冠疫苗面世后,股市里的聪明钱会去哪里?对手套板块有多大影响?- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-14-story-h1536429185.jsp
-----------------------------------------------------------------------------------------------------------------------
That's reason why some investment banks (IB) had started to revise glove sector outlook.........
Hereby to enclose the latest glove preview & outlook by IB...
Macquarie downgrades Top Glove to 'underperform', halves target price as earnings could normalise in 2H21
(theedgemarkets.com / September 10, 2020 17:36 pm +08)
##https://www.theedgemarkets.com/article/macquarie-downgrades-top-glove-underperform-halves-target-price-earnings-could-normalise
JP Morgan pegs these glove makers' fair value at up to half their market price, says supernormal cycle is over
(theedgemarkets.com / December 12, 2020 00:16 am +08)
##https://www.theedgemarkets.com/article/jp-morgan-pegs-these-glove-makers-fair-value-half-their-market-price-says-supernormal-cycle
PublicInvest Research downgrades Top Glove to 'neutral' on ESG concerns
(theedgemarkets.com / December 18, 2020 10:38 am +08)
##https://www.theedgemarkets.com/article/publicinvest-research-downgrades-top-glove-neutral-esg-concerns
Revision :-
Macquarie - TP : 5.45
JP Morgan - TP : 3.50
PB IB - TP : 7.30
-----------------------------------------------------------------------------------------------------------------------
Keyman188 comment is only for those need to heard & perceive...
Save your hard earned money to avoid fighting with Big Funds...
Sometime need to follow the "wind" where to come...where to blow....
2020-12-31 15:25 | Report Abuse
Keyman188 not so expert to trade share worrr....
Professionals & Expertise say buy then buy lorrrr....
Professionals & Expertise say sell then sell lorrrr....
Keyman188 always very nervous, naive & coward to become shark & crocodile victim mahhh.............
Posted by ssdn02 > Dec 31, 2020 2:37 PM | Report Abuse
@keyman188! JP Morgan is a out dated museum. They will be history soon. Time to buy more.
2020-12-31 14:33 | Report Abuse
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Keyman188 very scared to become warrior or hero...
Keyman188 no harm better listen more to Professionals & Expertise to avoid become shark & crocodile victim...
Keyman188 not the professional or expertise...Let the expertise give more advise to the market...
为什么想投资科技股就必须关注美国大选最终结果?马股橱窗粉饰之后会有调整吗? - 陈剑
##https://klse.i3investor.com/blogs/kianweiaritcles/2020-12-26-story-h1538398268.jsp
业绩这么好为何股价涨不动?近期手套股业绩和股价走势背离最完整讲解!- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-20-story-h1536526427.jsp
新冠疫苗面世后,股市里的聪明钱会去哪里?对手套板块有多大影响?- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-14-story-h1536429185.jsp
-----------------------------------------------------------------------------------------------------------------------
That's reason why some investment banks (IB) had started to revise glove sector outlook.........
Hereby to enclose the latest glove preview & outlook by IB...
Macquarie downgrades Top Glove to 'underperform', halves target price as earnings could normalise in 2H21
(theedgemarkets.com / September 10, 2020 17:36 pm +08)
##https://www.theedgemarkets.com/article/macquarie-downgrades-top-glove-underperform-halves-target-price-earnings-could-normalise
JP Morgan pegs these glove makers' fair value at up to half their market price, says supernormal cycle is over
(theedgemarkets.com / December 12, 2020 00:16 am +08)
##https://www.theedgemarkets.com/article/jp-morgan-pegs-these-glove-makers-fair-value-half-their-market-price-says-supernormal-cycle
PublicInvest Research downgrades Top Glove to 'neutral' on ESG concerns
(theedgemarkets.com / December 18, 2020 10:38 am +08)
##https://www.theedgemarkets.com/article/publicinvest-research-downgrades-top-glove-neutral-esg-concerns
Revision :-
Macquarie - TP : 5.45
JP Morgan - TP : 3.50
PB IB - TP : 7.30
2020-12-31 14:32 | Report Abuse
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Keyman188 very scared to become warrior or hero...
Keyman188 no harm better listen more to Professionals & Expertise to avoid become shark & crocodile victim...
Keyman188 not the professional or expertise...Let the expertise give more advise to the market...
为什么想投资科技股就必须关注美国大选最终结果?马股橱窗粉饰之后会有调整吗? - 陈剑
##https://klse.i3investor.com/blogs/kianweiaritcles/2020-12-26-story-h1538398268.jsp
业绩这么好为何股价涨不动?近期手套股业绩和股价走势背离最完整讲解!- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-20-story-h1536526427.jsp
新冠疫苗面世后,股市里的聪明钱会去哪里?对手套板块有多大影响?- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-14-story-h1536429185.jsp
-----------------------------------------------------------------------------------------------------------------------
That's reason why some investment banks (IB) had started to revise glove sector outlook.........
Hereby to enclose the latest glove preview & outlook by IB...
Macquarie downgrades Top Glove to 'underperform', halves target price as earnings could normalise in 2H21
(theedgemarkets.com / September 10, 2020 17:36 pm +08)
##https://www.theedgemarkets.com/article/macquarie-downgrades-top-glove-underperform-halves-target-price-earnings-could-normalise
JP Morgan pegs these glove makers' fair value at up to half their market price, says supernormal cycle is over
(theedgemarkets.com / December 12, 2020 00:16 am +08)
##https://www.theedgemarkets.com/article/jp-morgan-pegs-these-glove-makers-fair-value-half-their-market-price-says-supernormal-cycle
PublicInvest Research downgrades Top Glove to 'neutral' on ESG concerns
(theedgemarkets.com / December 18, 2020 10:38 am +08)
##https://www.theedgemarkets.com/article/publicinvest-research-downgrades-top-glove-neutral-esg-concerns
Revision :-
Macquarie - TP : 5.45
JP Morgan - TP : 3.50
PB IB - TP : 7.30
2020-12-31 10:01 | Report Abuse
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Keyman188 very scared to become warrior or hero...
Keyman188 no harm better listen more to Professionals & Expertise to avoid become shark & crocodile victim...
Keyman188 not the professional or expertise...Let the expertise give more advise to the market...
为什么想投资科技股就必须关注美国大选最终结果?马股橱窗粉饰之后会有调整吗? - 陈剑
##https://klse.i3investor.com/blogs/kianweiaritcles/2020-12-26-story-h1538398268.jsp
业绩这么好为何股价涨不动?近期手套股业绩和股价走势背离最完整讲解!- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-20-story-h1536526427.jsp
新冠疫苗面世后,股市里的聪明钱会去哪里?对手套板块有多大影响?- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-14-story-h1536429185.jsp
-----------------------------------------------------------------------------------------------------------------------
That's reason why some investment banks (IB) had started to revise glove sector outlook.........
Hereby to enclose the latest glove preview & outlook by IB...
Macquarie downgrades Top Glove to 'underperform', halves target price as earnings could normalise in 2H21
(theedgemarkets.com / September 10, 2020 17:36 pm +08)
##https://www.theedgemarkets.com/article/macquarie-downgrades-top-glove-underperform-halves-target-price-earnings-could-normalise
JP Morgan pegs these glove makers' fair value at up to half their market price, says supernormal cycle is over
(theedgemarkets.com / December 12, 2020 00:16 am +08)
##https://www.theedgemarkets.com/article/jp-morgan-pegs-these-glove-makers-fair-value-half-their-market-price-says-supernormal-cycle
PublicInvest Research downgrades Top Glove to 'neutral' on ESG concerns
(theedgemarkets.com / December 18, 2020 10:38 am +08)
##https://www.theedgemarkets.com/article/publicinvest-research-downgrades-top-glove-neutral-esg-concerns
Revision :-
Macquarie - TP : 5.45
JP Morgan - TP : 3.50
PB IB - TP : 7.30
2020-12-31 10:01 | Report Abuse
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Keyman188 very scared to become warrior or hero...
Keyman188 no harm better listen more to Professionals & Expertise to avoid become shark & crocodile victim...
Keyman188 not the professional or expertise...Let the expertise give more advise to the market...
为什么想投资科技股就必须关注美国大选最终结果?马股橱窗粉饰之后会有调整吗? - 陈剑
##https://klse.i3investor.com/blogs/kianweiaritcles/2020-12-26-story-h1538398268.jsp
业绩这么好为何股价涨不动?近期手套股业绩和股价走势背离最完整讲解!- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-20-story-h1536526427.jsp
新冠疫苗面世后,股市里的聪明钱会去哪里?对手套板块有多大影响?- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-14-story-h1536429185.jsp
-----------------------------------------------------------------------------------------------------------------------
That's reason why some investment banks (IB) had started to revise glove sector outlook.........
Hereby to enclose the latest glove preview & outlook by IB...
Macquarie downgrades Top Glove to 'underperform', halves target price as earnings could normalise in 2H21
(theedgemarkets.com / September 10, 2020 17:36 pm +08)
##https://www.theedgemarkets.com/article/macquarie-downgrades-top-glove-underperform-halves-target-price-earnings-could-normalise
JP Morgan pegs these glove makers' fair value at up to half their market price, says supernormal cycle is over
(theedgemarkets.com / December 12, 2020 00:16 am +08)
##https://www.theedgemarkets.com/article/jp-morgan-pegs-these-glove-makers-fair-value-half-their-market-price-says-supernormal-cycle
PublicInvest Research downgrades Top Glove to 'neutral' on ESG concerns
(theedgemarkets.com / December 18, 2020 10:38 am +08)
##https://www.theedgemarkets.com/article/publicinvest-research-downgrades-top-glove-neutral-esg-concerns
Revision :-
Macquarie - TP : 5.45
JP Morgan - TP : 3.50
PB IB - TP : 7.30
2020-12-30 20:33 | Report Abuse
Copper price has gradually increased from $2100 (Mar'20) until now $3500 ++
"This makes copper prices a good leading indicator of the economic cycle. For example, if orders for copper are being canceled or delayed, the price will drop. This can be a leading indicator that an economic recession is at hand. Conversely, if orders for copper are rising, the price will go up"
What do copper prices indicate about the economy?
"In general, rising copper prices have indicated strong demand and global economic strength; lower prices, a weaker economy. Historically, the price of copper has been strongly correlated with the price of gold, the Chinese economy, world trade, and most consistently, with the price of oil."
How does copper affect the economy?
"Copper mining is controversial because it adds a great deal to the economy, while also striping the land of its resources, and leaving a wake of poor poverty and ill health. Because of the danger, high wages, and frequent layoffs many mining towns see very high unemployment rates."
2020-12-30 20:28 | Report Abuse
Copper price from $ 2100 (Mar'20) until now $3500++...
aiya...most of the traders just looking glove price only...
Where got traders have observed the copper price.....
Posted by Cedric Chan CA > Dec 30, 2020 8:15 PM | Report Abuse
JAG & TAWIN (COPPER)
电话响起,是老板Ah Fai打来
阿丰一接电话,
就听到电话另一头传来紧张的说话:
“铜又涨了,快点lock in order,给cash lock多一点,不然当市场热了,我们的产品没有原料”
以上简短的对话,如果发生在同一个行业的老板都这样想,那么不需要等到经济回来,基本原物料都涨疯了。
山江水暖鸭先知,虽然普通人还感觉到寒冷,可是鸭子长期在水里,触觉可比一般人灵敏得多。
铜价今晚又涨了,离历史新高还不到30%
为什么看铜?
就像黄金在冬天时避险,
春天时铜是所有有色金属的先行指标,
因为它的工业属性很强,
从汽车到家电,从科技产品到输电,
工业半成品/成品大多数都需要用到铜。
2020-12-30 17:11 | Report Abuse
AstraZeneca-Oxford Covid Vaccine Gains First Clearance With U.K. Nod
(December 30, 2020, 3:06 PM GMT+8 Updated on December 30, 2020, 4:08 PM GMT+8)
~ Vaccinations to start in new year as cases rise across Britain
~ Recipients to get second shot within 12 weeks of first one
AstraZeneca Plc and the University of Oxford’s Covid-19 vaccine won U.K. clearance, marking the first approval worldwide for a shot that’s faced questions but will be key to mass immunizations.
The vaccine will be prioritized for the country’s most vulnerable groups, with shots starting Monday, according to the government. It’s the second coronavirus injection to be cleared for emergency use in the U.K. after Pfizer Inc. and BioNTech SE’s in early December.
The move will help the U.K. ramp up vaccination and provides vindication for the homegrown shot, which has drawn scrutiny over discrepancies in its clinical-trial results. The shot can be deployed swiftly because it’s easier to transport and store than the Pfizer-BioNTech one, requiring only refrigerator temperatures rather than deep freezing. The U.K. has bought 100 million doses.
A first dose of the AstraZeneca-Oxford vaccine will be given to as many people as possible, followed by a second shot four to 12 weeks later. A government advisory group said the priority should be to vaccinate large numbers as quickly as possible rather than completing a two-dose regimen right away.
AstraZeneca shares rose as much as 1.8% early Wednesday in London.
The approval comes as the U.K. seals its divorce from the European Union with a trade deal and tightens lockdowns amid a new surge on coronavirus infections that’s straining hospitals. The U.K. reported a record number of fresh daily Covid cases Tuesday, as a new variant of the pathogen raises concern globally.
The country’s vaccination program has advanced quickly, with more than 600,000 people given shots by Christmas. The U.S. is immunizing an average of only 200,000 people a day, with many states having used just a small percentage of the shipments sent to them this month.
“We will start to get ahead of the pandemic, protect health and economies when the vulnerable are vaccinated everywhere,” said Andrew Pollard, Oxford’s lead investigator for the vaccine.
When patients were given two full shots, the vaccine was 62% effective -- less than the Pfizer-BioNTech shot and another from Moderna Inc. A group that accidentally received half of the first dose showed better protection, with efficacy reaching 90%. But participants were 55 years old or less, and because older people who are most at risk of severe Covid-19 often show more sluggish immune responses, the results leave some doubt as to whether the efficacy will stand up to further testing.
Cont...
## https://www.bloomberg.com/news/articles/2020-12-30/astra-oxford-covid-vaccine-gains-first-clearance-with-u-k-nod?srnd=premium-asia
2020-12-30 17:11 | Report Abuse
AstraZeneca-Oxford Covid Vaccine Gains First Clearance With U.K. Nod
(December 30, 2020, 3:06 PM GMT+8 Updated on December 30, 2020, 4:08 PM GMT+8)
~ Vaccinations to start in new year as cases rise across Britain
~ Recipients to get second shot within 12 weeks of first one
AstraZeneca Plc and the University of Oxford’s Covid-19 vaccine won U.K. clearance, marking the first approval worldwide for a shot that’s faced questions but will be key to mass immunizations.
The vaccine will be prioritized for the country’s most vulnerable groups, with shots starting Monday, according to the government. It’s the second coronavirus injection to be cleared for emergency use in the U.K. after Pfizer Inc. and BioNTech SE’s in early December.
The move will help the U.K. ramp up vaccination and provides vindication for the homegrown shot, which has drawn scrutiny over discrepancies in its clinical-trial results. The shot can be deployed swiftly because it’s easier to transport and store than the Pfizer-BioNTech one, requiring only refrigerator temperatures rather than deep freezing. The U.K. has bought 100 million doses.
A first dose of the AstraZeneca-Oxford vaccine will be given to as many people as possible, followed by a second shot four to 12 weeks later. A government advisory group said the priority should be to vaccinate large numbers as quickly as possible rather than completing a two-dose regimen right away.
AstraZeneca shares rose as much as 1.8% early Wednesday in London.
The approval comes as the U.K. seals its divorce from the European Union with a trade deal and tightens lockdowns amid a new surge on coronavirus infections that’s straining hospitals. The U.K. reported a record number of fresh daily Covid cases Tuesday, as a new variant of the pathogen raises concern globally.
The country’s vaccination program has advanced quickly, with more than 600,000 people given shots by Christmas. The U.S. is immunizing an average of only 200,000 people a day, with many states having used just a small percentage of the shipments sent to them this month.
“We will start to get ahead of the pandemic, protect health and economies when the vulnerable are vaccinated everywhere,” said Andrew Pollard, Oxford’s lead investigator for the vaccine.
When patients were given two full shots, the vaccine was 62% effective -- less than the Pfizer-BioNTech shot and another from Moderna Inc. A group that accidentally received half of the first dose showed better protection, with efficacy reaching 90%. But participants were 55 years old or less, and because older people who are most at risk of severe Covid-19 often show more sluggish immune responses, the results leave some doubt as to whether the efficacy will stand up to further testing.
Cont...
## https://www.bloomberg.com/news/articles/2020-12-30/astra-oxford-covid-vaccine-gains-first-clearance-with-u-k-nod?srnd=premium-asia
2020-12-30 17:10 | Report Abuse
AstraZeneca-Oxford Covid Vaccine Gains First Clearance With U.K. Nod
(December 30, 2020, 3:06 PM GMT+8 Updated on December 30, 2020, 4:08 PM GMT+8)
~ Vaccinations to start in new year as cases rise across Britain
~ Recipients to get second shot within 12 weeks of first one
AstraZeneca Plc and the University of Oxford’s Covid-19 vaccine won U.K. clearance, marking the first approval worldwide for a shot that’s faced questions but will be key to mass immunizations.
The vaccine will be prioritized for the country’s most vulnerable groups, with shots starting Monday, according to the government. It’s the second coronavirus injection to be cleared for emergency use in the U.K. after Pfizer Inc. and BioNTech SE’s in early December.
The move will help the U.K. ramp up vaccination and provides vindication for the homegrown shot, which has drawn scrutiny over discrepancies in its clinical-trial results. The shot can be deployed swiftly because it’s easier to transport and store than the Pfizer-BioNTech one, requiring only refrigerator temperatures rather than deep freezing. The U.K. has bought 100 million doses.
A first dose of the AstraZeneca-Oxford vaccine will be given to as many people as possible, followed by a second shot four to 12 weeks later. A government advisory group said the priority should be to vaccinate large numbers as quickly as possible rather than completing a two-dose regimen right away.
AstraZeneca shares rose as much as 1.8% early Wednesday in London.
The approval comes as the U.K. seals its divorce from the European Union with a trade deal and tightens lockdowns amid a new surge on coronavirus infections that’s straining hospitals. The U.K. reported a record number of fresh daily Covid cases Tuesday, as a new variant of the pathogen raises concern globally.
The country’s vaccination program has advanced quickly, with more than 600,000 people given shots by Christmas. The U.S. is immunizing an average of only 200,000 people a day, with many states having used just a small percentage of the shipments sent to them this month.
“We will start to get ahead of the pandemic, protect health and economies when the vulnerable are vaccinated everywhere,” said Andrew Pollard, Oxford’s lead investigator for the vaccine.
When patients were given two full shots, the vaccine was 62% effective -- less than the Pfizer-BioNTech shot and another from Moderna Inc. A group that accidentally received half of the first dose showed better protection, with efficacy reaching 90%. But participants were 55 years old or less, and because older people who are most at risk of severe Covid-19 often show more sluggish immune responses, the results leave some doubt as to whether the efficacy will stand up to further testing.
Cont...
## https://www.bloomberg.com/news/articles/2020-12-30/astra-oxford-covid-vaccine-gains-first-clearance-with-u-k-nod?srnd=premium-asia
2020-12-30 17:10 | Report Abuse
AstraZeneca-Oxford Covid Vaccine Gains First Clearance With U.K. Nod
(December 30, 2020, 3:06 PM GMT+8 Updated on December 30, 2020, 4:08 PM GMT+8)
~ Vaccinations to start in new year as cases rise across Britain
~ Recipients to get second shot within 12 weeks of first one
AstraZeneca Plc and the University of Oxford’s Covid-19 vaccine won U.K. clearance, marking the first approval worldwide for a shot that’s faced questions but will be key to mass immunizations.
The vaccine will be prioritized for the country’s most vulnerable groups, with shots starting Monday, according to the government. It’s the second coronavirus injection to be cleared for emergency use in the U.K. after Pfizer Inc. and BioNTech SE’s in early December.
The move will help the U.K. ramp up vaccination and provides vindication for the homegrown shot, which has drawn scrutiny over discrepancies in its clinical-trial results. The shot can be deployed swiftly because it’s easier to transport and store than the Pfizer-BioNTech one, requiring only refrigerator temperatures rather than deep freezing. The U.K. has bought 100 million doses.
A first dose of the AstraZeneca-Oxford vaccine will be given to as many people as possible, followed by a second shot four to 12 weeks later. A government advisory group said the priority should be to vaccinate large numbers as quickly as possible rather than completing a two-dose regimen right away.
AstraZeneca shares rose as much as 1.8% early Wednesday in London.
The approval comes as the U.K. seals its divorce from the European Union with a trade deal and tightens lockdowns amid a new surge on coronavirus infections that’s straining hospitals. The U.K. reported a record number of fresh daily Covid cases Tuesday, as a new variant of the pathogen raises concern globally.
The country’s vaccination program has advanced quickly, with more than 600,000 people given shots by Christmas. The U.S. is immunizing an average of only 200,000 people a day, with many states having used just a small percentage of the shipments sent to them this month.
“We will start to get ahead of the pandemic, protect health and economies when the vulnerable are vaccinated everywhere,” said Andrew Pollard, Oxford’s lead investigator for the vaccine.
When patients were given two full shots, the vaccine was 62% effective -- less than the Pfizer-BioNTech shot and another from Moderna Inc. A group that accidentally received half of the first dose showed better protection, with efficacy reaching 90%. But participants were 55 years old or less, and because older people who are most at risk of severe Covid-19 often show more sluggish immune responses, the results leave some doubt as to whether the efficacy will stand up to further testing.
Cont...
## https://www.bloomberg.com/news/articles/2020-12-30/astra-oxford-covid-vaccine-gains-first-clearance-with-u-k-nod?srnd=premium-asia
2020-12-30 17:03 | Report Abuse
Today give chance to glove sector rebound also don't want to rebound..
Black candlestick pattern some more....
Last 4 min dumping like hell some more....
What can you expect for upcoming period !!!..........
2020-12-30 16:52 | Report Abuse
Fortune teller....Why not 6.30 ???...
Suddenly u-turn to 5.98...more worst than yesterday...
So how ???.................kekeke...kekeke.........
Posted by Tyco > Dec 30, 2020 3:28 PM | Report Abuse
Today closing sure 6.30 above and follow to green tomorrow
Next week very very green
Confirm
Its always the trend
2020-12-30 16:38 | Report Abuse
Oxford-AstraZeneca Covid vaccine approved by UK regulator
(PUBLISHED WED, DEC 30 20201:57 AM ESTUPDATED WED, DEC 30 20202:38 AM EST)
~The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has been authorized for emergency use in the U.K., marking another step in the global battle against the pandemic.
~ The shot is expected to be rolled out next week and would be added to the Pfizer-BioNTech vaccine which has so far been given to 600,000 people in the U.K., according to government statistics.
LONDON — The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has been authorized for emergency use in the U.K., marking another step in the global battle against the pandemic.
The shot is expected to be rolled out next week and will be added to a Covid-19 immunization program started by Britain in December. So far, the Pfizer-BioNTech vaccine has been given to 600,000 people in the U.K., according to government statistics.
In a statement, AstraZeneca said the first doses of the vaccine were being released Wednesday “so that vaccinations may begin early in the New Year.”
It added that it “aims to supply millions of doses in the first quarter” as part of its deal with the U.K. government to supply up to 100 million doses in total. As a two-dose vaccine, the agreement means up to 50 million people in the U.K., which has a population of around 66 million, could be inoculated.
However, the U.K. government said in a statement Wednesday that the Joint Committee on Vaccination and Immunisation, which advises it on immunization programs, had recommended that the “priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible.”
“Everyone will still receive their second dose and this will be within 12 weeks of their first. The second dose completes the course and is important for longer term protection,” it added.
U.K. government minister Michael Gove had said Monday that the approval of the Oxford-AstraZeneca vaccine could accelerate the lifting of strict lockdowns in the country, which effectively canceled Christmas festivities for millions.
Cases have surged in London and southern England with significant pressure being placed on hospitals. A new coronavirus variant found in the U.K. is reportedly more transmissible and has led to travel restrictions for people wanting to leave the country.
‘An important day’
The Oxford-AstraZeneca vaccine allows the U.K. to significantly ramp up its inoculation program. It’s also cheaper than others and does not need to be kept at ultra-low temperatures.
AstraZeneca’s Chief Executive Officer Pascal Soriot said in a statement that “today is an important day for millions of people in the U.K. who will get access to this new vaccine. It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit.”
AstraZeneca’s vaccine is a viral vector inoculation that is based on a weakened version of a common cold virus that causes infections in chimpanzees. It is designed to prime the immune system to attack the coronavirus, known as SARS-CoV-2, if it later infects the body.
Dr. Richard Horton, editor-in-chief of The Lancet medical journal, told CNBC in December that these advantages meant it could be used around the globe more effectively.
“The Oxford AstraZeneca vaccine is the vaccine right now that is going to be able to immunize the planet more effectively, more rapidly than any other vaccine we have,” Horton said, adding that it was important to think about vaccine immunization on a global scale “because even if we immunize one country, the threat then is you reintroduce the virus from another country that is not protected.”
Confusion around its trial data in November led to some criticism of AstraZeneca. The initial figures suggested that the vaccine can help reduce the spread of Covid-19, as well as prevent illness and death. That study also found it had an effectiveness of 62% for trial participants given two full doses, but 90% for a subgroup given half a dose followed by a full dose.
Chief of the White House’s Operation Warp Speed, Moncef Slaoui, and others in the U.S. have expressed concern over the age group tested, saying the 90% efficacy was only shown for the lowest risk group, which numbered 2,741 people below age 55.
AstraZeneca said Wednesday that “additional safety and efficacy data for the vaccine will continue to accumulate from ongoing clinical trials.” It added that it continues to work with regulatory authorities around the world “to support their ongoing rolling reviews for emergency supply or conditional marketing authorisation during the health crisis.”
2020-12-30 16:36 | Report Abuse
Oxford-AstraZeneca Covid vaccine approved by UK regulator
(PUBLISHED WED, DEC 30 20201:57 AM ESTUPDATED WED, DEC 30 20202:38 AM EST)
~The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has been authorized for emergency use in the U.K., marking another step in the global battle against the pandemic.
~ The shot is expected to be rolled out next week and would be added to the Pfizer-BioNTech vaccine which has so far been given to 600,000 people in the U.K., according to government statistics.
LONDON — The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has been authorized for emergency use in the U.K., marking another step in the global battle against the pandemic.
The shot is expected to be rolled out next week and will be added to a Covid-19 immunization program started by Britain in December. So far, the Pfizer-BioNTech vaccine has been given to 600,000 people in the U.K., according to government statistics.
In a statement, AstraZeneca said the first doses of the vaccine were being released Wednesday “so that vaccinations may begin early in the New Year.”
It added that it “aims to supply millions of doses in the first quarter” as part of its deal with the U.K. government to supply up to 100 million doses in total. As a two-dose vaccine, the agreement means up to 50 million people in the U.K., which has a population of around 66 million, could be inoculated.
However, the U.K. government said in a statement Wednesday that the Joint Committee on Vaccination and Immunisation, which advises it on immunization programs, had recommended that the “priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible.”
“Everyone will still receive their second dose and this will be within 12 weeks of their first. The second dose completes the course and is important for longer term protection,” it added.
U.K. government minister Michael Gove had said Monday that the approval of the Oxford-AstraZeneca vaccine could accelerate the lifting of strict lockdowns in the country, which effectively canceled Christmas festivities for millions.
Cases have surged in London and southern England with significant pressure being placed on hospitals. A new coronavirus variant found in the U.K. is reportedly more transmissible and has led to travel restrictions for people wanting to leave the country.
‘An important day’
The Oxford-AstraZeneca vaccine allows the U.K. to significantly ramp up its inoculation program. It’s also cheaper than others and does not need to be kept at ultra-low temperatures.
AstraZeneca’s Chief Executive Officer Pascal Soriot said in a statement that “today is an important day for millions of people in the U.K. who will get access to this new vaccine. It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit.”
AstraZeneca’s vaccine is a viral vector inoculation that is based on a weakened version of a common cold virus that causes infections in chimpanzees. It is designed to prime the immune system to attack the coronavirus, known as SARS-CoV-2, if it later infects the body.
Dr. Richard Horton, editor-in-chief of The Lancet medical journal, told CNBC in December that these advantages meant it could be used around the globe more effectively.
“The Oxford AstraZeneca vaccine is the vaccine right now that is going to be able to immunize the planet more effectively, more rapidly than any other vaccine we have,” Horton said, adding that it was important to think about vaccine immunization on a global scale “because even if we immunize one country, the threat then is you reintroduce the virus from another country that is not protected.”
Confusion around its trial data in November led to some criticism of AstraZeneca. The initial figures suggested that the vaccine can help reduce the spread of Covid-19, as well as prevent illness and death. That study also found it had an effectiveness of 62% for trial participants given two full doses, but 90% for a subgroup given half a dose followed by a full dose.
Chief of the White House’s Operation Warp Speed, Moncef Slaoui, and others in the U.S. have expressed concern over the age group tested, saying the 90% efficacy was only shown for the lowest risk group, which numbered 2,741 people below age 55.
AstraZeneca said Wednesday that “additional safety and efficacy data for the vaccine will continue to accumulate from ongoing clinical trials.” It added that it continues to work with regulatory authorities around the world “to support their ongoing rolling reviews for emergency supply or conditional marketing authorisation during the health crisis.”
2020-12-30 16:36 | Report Abuse
Oxford-AstraZeneca Covid vaccine approved by UK regulator
(PUBLISHED WED, DEC 30 20201:57 AM ESTUPDATED WED, DEC 30 20202:38 AM EST)
~The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has been authorized for emergency use in the U.K., marking another step in the global battle against the pandemic.
~ The shot is expected to be rolled out next week and would be added to the Pfizer-BioNTech vaccine which has so far been given to 600,000 people in the U.K., according to government statistics.
LONDON — The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has been authorized for emergency use in the U.K., marking another step in the global battle against the pandemic.
The shot is expected to be rolled out next week and will be added to a Covid-19 immunization program started by Britain in December. So far, the Pfizer-BioNTech vaccine has been given to 600,000 people in the U.K., according to government statistics.
In a statement, AstraZeneca said the first doses of the vaccine were being released Wednesday “so that vaccinations may begin early in the New Year.”
It added that it “aims to supply millions of doses in the first quarter” as part of its deal with the U.K. government to supply up to 100 million doses in total. As a two-dose vaccine, the agreement means up to 50 million people in the U.K., which has a population of around 66 million, could be inoculated.
However, the U.K. government said in a statement Wednesday that the Joint Committee on Vaccination and Immunisation, which advises it on immunization programs, had recommended that the “priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible.”
“Everyone will still receive their second dose and this will be within 12 weeks of their first. The second dose completes the course and is important for longer term protection,” it added.
U.K. government minister Michael Gove had said Monday that the approval of the Oxford-AstraZeneca vaccine could accelerate the lifting of strict lockdowns in the country, which effectively canceled Christmas festivities for millions.
Cases have surged in London and southern England with significant pressure being placed on hospitals. A new coronavirus variant found in the U.K. is reportedly more transmissible and has led to travel restrictions for people wanting to leave the country.
‘An important day’
The Oxford-AstraZeneca vaccine allows the U.K. to significantly ramp up its inoculation program. It’s also cheaper than others and does not need to be kept at ultra-low temperatures.
AstraZeneca’s Chief Executive Officer Pascal Soriot said in a statement that “today is an important day for millions of people in the U.K. who will get access to this new vaccine. It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit.”
AstraZeneca’s vaccine is a viral vector inoculation that is based on a weakened version of a common cold virus that causes infections in chimpanzees. It is designed to prime the immune system to attack the coronavirus, known as SARS-CoV-2, if it later infects the body.
Dr. Richard Horton, editor-in-chief of The Lancet medical journal, told CNBC in December that these advantages meant it could be used around the globe more effectively.
“The Oxford AstraZeneca vaccine is the vaccine right now that is going to be able to immunize the planet more effectively, more rapidly than any other vaccine we have,” Horton said, adding that it was important to think about vaccine immunization on a global scale “because even if we immunize one country, the threat then is you reintroduce the virus from another country that is not protected.”
Confusion around its trial data in November led to some criticism of AstraZeneca. The initial figures suggested that the vaccine can help reduce the spread of Covid-19, as well as prevent illness and death. That study also found it had an effectiveness of 62% for trial participants given two full doses, but 90% for a subgroup given half a dose followed by a full dose.
Chief of the White House’s Operation Warp Speed, Moncef Slaoui, and others in the U.S. have expressed concern over the age group tested, saying the 90% efficacy was only shown for the lowest risk group, which numbered 2,741 people below age 55.
AstraZeneca said Wednesday that “additional safety and efficacy data for the vaccine will continue to accumulate from ongoing clinical trials.” It added that it continues to work with regulatory authorities around the world “to support their ongoing rolling reviews for emergency supply or conditional marketing authorisation during the health crisis.”
## https://www.cnbc.com/2020/12/30/oxford-astrazeneca-covid-vaccine-approved-by-uk-regulator-.html
2020-12-30 16:36 | Report Abuse
Oxford-AstraZeneca Covid vaccine approved by UK regulator
(PUBLISHED WED, DEC 30 20201:57 AM ESTUPDATED WED, DEC 30 20202:38 AM EST)
~The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has been authorized for emergency use in the U.K., marking another step in the global battle against the pandemic.
~ The shot is expected to be rolled out next week and would be added to the Pfizer-BioNTech vaccine which has so far been given to 600,000 people in the U.K., according to government statistics.
LONDON — The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has been authorized for emergency use in the U.K., marking another step in the global battle against the pandemic.
The shot is expected to be rolled out next week and will be added to a Covid-19 immunization program started by Britain in December. So far, the Pfizer-BioNTech vaccine has been given to 600,000 people in the U.K., according to government statistics.
In a statement, AstraZeneca said the first doses of the vaccine were being released Wednesday “so that vaccinations may begin early in the New Year.”
It added that it “aims to supply millions of doses in the first quarter” as part of its deal with the U.K. government to supply up to 100 million doses in total. As a two-dose vaccine, the agreement means up to 50 million people in the U.K., which has a population of around 66 million, could be inoculated.
However, the U.K. government said in a statement Wednesday that the Joint Committee on Vaccination and Immunisation, which advises it on immunization programs, had recommended that the “priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible.”
“Everyone will still receive their second dose and this will be within 12 weeks of their first. The second dose completes the course and is important for longer term protection,” it added.
U.K. government minister Michael Gove had said Monday that the approval of the Oxford-AstraZeneca vaccine could accelerate the lifting of strict lockdowns in the country, which effectively canceled Christmas festivities for millions.
Cases have surged in London and southern England with significant pressure being placed on hospitals. A new coronavirus variant found in the U.K. is reportedly more transmissible and has led to travel restrictions for people wanting to leave the country.
‘An important day’
The Oxford-AstraZeneca vaccine allows the U.K. to significantly ramp up its inoculation program. It’s also cheaper than others and does not need to be kept at ultra-low temperatures.
AstraZeneca’s Chief Executive Officer Pascal Soriot said in a statement that “today is an important day for millions of people in the U.K. who will get access to this new vaccine. It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit.”
AstraZeneca’s vaccine is a viral vector inoculation that is based on a weakened version of a common cold virus that causes infections in chimpanzees. It is designed to prime the immune system to attack the coronavirus, known as SARS-CoV-2, if it later infects the body.
Dr. Richard Horton, editor-in-chief of The Lancet medical journal, told CNBC in December that these advantages meant it could be used around the globe more effectively.
“The Oxford AstraZeneca vaccine is the vaccine right now that is going to be able to immunize the planet more effectively, more rapidly than any other vaccine we have,” Horton said, adding that it was important to think about vaccine immunization on a global scale “because even if we immunize one country, the threat then is you reintroduce the virus from another country that is not protected.”
Confusion around its trial data in November led to some criticism of AstraZeneca. The initial figures suggested that the vaccine can help reduce the spread of Covid-19, as well as prevent illness and death. That study also found it had an effectiveness of 62% for trial participants given two full doses, but 90% for a subgroup given half a dose followed by a full dose.
Chief of the White House’s Operation Warp Speed, Moncef Slaoui, and others in the U.S. have expressed concern over the age group tested, saying the 90% efficacy was only shown for the lowest risk group, which numbered 2,741 people below age 55.
AstraZeneca said Wednesday that “additional safety and efficacy data for the vaccine will continue to accumulate from ongoing clinical trials.” It added that it continues to work with regulatory authorities around the world “to support their ongoing rolling reviews for emergency supply or conditional marketing authorisation during the health crisis.”
## https://www.cnbc.com/2020/12/30/oxford-astrazeneca-covid-vaccine-approved-by-uk-regulator-.html
2020-12-30 16:28 | Report Abuse
Today give chance to glove sector rebound also don't want to rebound..
Black candlestick pattern some more....
What can you expect for upcoming period !!!..........
2020-12-30 16:28 | Report Abuse
Today give chance to glove sector rebound also don't want to rebound..
Black candlestick pattern some more....
What can you expect for upcoming period !!!..........
2020-12-30 16:27 | Report Abuse
Today give chance to glove sector rebound also don't want to rebound..
Black candlestick pattern some more....
What can you expect for upcoming period !!!..........
2020-12-30 16:27 | Report Abuse
Today give chance to glove sector rebound also don't want to rebound..
Black candlestick pattern some more....
What can you expect for upcoming period !!!..........
2020-12-30 15:50 | Report Abuse
Keyman188 always like to repeat & repeat constructive solutions to remind ourselves...
Aiyo...why so many glove investors so worry whatever negative news...
Keep on defending whatever bad news...
If you are always talking keep it for long term, why so worry share price drop !!!...
You all come out so much noise unless you all also started to doubt your own perception & decision!!!...
Unless a lot of short term investors keep on betting short term profit !!!......
Unless a lot of short term investors keep on betting "structured warrant" for short term profit !!!......
Posted by Agjl > Dec 30, 2020 3:47 PM | Report Abuse
No need to make such comment my fren.
Give constructive and positive comment and solution...
2020-12-30 15:45 | Report Abuse
Seem like you already stuck at the high floor lorrr....
Kesian lor....yum gong lorr....
That's why so desperately ask victims here to push for you to run....
Posted by Tyco > Dec 30, 2020 3:41 PM | Report Abuse
Next week Supermax no more 7 below
Should be week 1. 7-8 , week 2. 8-9 week 3. 9-10
2020-12-30 15:42 | Report Abuse
Wahhh.....Now fortune teller inform us what is upcoming price worrr...
Aiya....just keep us 4 ekor what to buy today better lahh...
So we can hamtam kaw kaw tonight..........kekeke...kekeke....
Posted by Tyco > Dec 30, 2020 3:28 PM | Report Abuse
Today closing sure 6.30 above and follow to green tomorrow
Next week very very green
Confirm
Its always the trend
Posted by Tyco > Dec 30, 2020 3:30 PM | Report Abuse
BY 15th January 2021 9-10.00 should achieve
2020-12-30 15:10 | Report Abuse
Kesian...kesian...
Seem like victim stuck the middle ring road liao...
That's why too hot...
Posted by Tyco > Dec 30, 2020 3:08 PM | Report Abuse
Keyman188 The Dogs dont laugh and bark so loud yet,tomorrow next week 4th Jan most of you dogs will back to cave howling
2020-12-30 15:04 | Report Abuse
Keyman188 feel a bit nervous & naive...
Something is NOT RIGHT...
Suddenly announced suspended for 1 hour but until now no special announcement on the suspension reason...
If normally having good new at this selling pressure, sure immediately announce to the public then more supportive...
But today Keyman188 really felt like "Abnormal" incidents..........
Keyman188 is humble person, strongly advise more alert...more cautious...
2020-12-30 14:20 | Report Abuse
Keyman188 feel a bit nervous & naive...
Something is NOT RIGHT...
Suddenly announced suspended for 1 hour but until now no special announcement on the suspension reason...
If normally having good new at this selling pressure, sure immediately announce to the public then more supportive...
But today Keyman188 really felt like "Abnormal" incidents..........
Keyman188 is humble person, strongly advise more alert...more cautious...
2020-12-30 14:18 | Report Abuse
Keyman188 feel a bit nervous & naive...
Something is NOT RIGHT...
Suddenly announced suspended for 1 hour but until now no special announcement on the suspension reason...
If normally having good new at this selling pressure, sure immediately announce to the public then more supportive...
But today Keyman188 really felt like "Abnormal" incidents..........
Keyman188 is humble person, strongly advise more alert...more cautious...
2020-12-30 12:18 | Report Abuse
Keyman188 is very broke & poor investor....
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Keyman188 very scared to become warrior or hero...
Keyman188 no harm better listen more to Professionals & Expertise to avoid become shark & crocodile victim...
Keyman188 not the professional or expertise...Let the expertise give more advise to the market...
为什么想投资科技股就必须关注美国大选最终结果?马股橱窗粉饰之后会有调整吗? - 陈剑
##https://klse.i3investor.com/blogs/kianweiaritcles/2020-12-26-story-h1538398268.jsp
业绩这么好为何股价涨不动?近期手套股业绩和股价走势背离最完整讲解!- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-20-story-h1536526427.jsp
新冠疫苗面世后,股市里的聪明钱会去哪里?对手套板块有多大影响?- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-14-story-h1536429185.jsp
-----------------------------------------------------------------------------------------------------------------------
That's reason why some investment banks (IB) had started to revise glove sector outlook.........
Hereby to enclose the latest glove preview & outlook by IB...
Macquarie downgrades Top Glove to 'underperform', halves target price as earnings could normalise in 2H21
(theedgemarkets.com / September 10, 2020 17:36 pm +08)
##https://www.theedgemarkets.com/article/macquarie-downgrades-top-glove-underperform-halves-target-price-earnings-could-normalise
JP Morgan pegs these glove makers' fair value at up to half their market price, says supernormal cycle is over
(theedgemarkets.com / December 12, 2020 00:16 am +08)
##https://www.theedgemarkets.com/article/jp-morgan-pegs-these-glove-makers-fair-value-half-their-market-price-says-supernormal-cycle
PublicInvest Research downgrades Top Glove to 'neutral' on ESG concerns
(theedgemarkets.com / December 18, 2020 10:38 am +08)
##https://www.theedgemarkets.com/article/publicinvest-research-downgrades-top-glove-neutral-esg-concerns
Revision :-
Macquarie - TP : 5.45
JP Morgan - TP : 3.50
PB IB - TP : 7.30
2020-12-30 10:13 | Report Abuse
Keyman188 a bit nervous & naive...
May I know EPF got share at Supermax mehhh !!!!........
Need some guidance from Sifu or Expertise here lahhh......
2020-12-30 10:11 | Report Abuse
Keyman188 a bit nervous & naive...
May I know EPF got share at Supermax mehhh !!!!........
2020-12-30 08:49 | Report Abuse
Keyman188 is very broke & poor investor....
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Keyman188 very scared to become warrior or hero...
Keyman188 no harm better listen more to Professionals & Expertise to avoid become shark & crocodile victim...
Keyman188 not the professional or expertise...Let the expertise give more advise to the market...
为什么想投资科技股就必须关注美国大选最终结果?马股橱窗粉饰之后会有调整吗? - 陈剑
##https://klse.i3investor.com/blogs/kianweiaritcles/2020-12-26-story-h1538398268.jsp
业绩这么好为何股价涨不动?近期手套股业绩和股价走势背离最完整讲解!- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-20-story-h1536526427.jsp
新冠疫苗面世后,股市里的聪明钱会去哪里?对手套板块有多大影响?- 陈剑
## https://klse.i3investor.com/blogs/kianweiaritcles/2020-11-14-story-h1536429185.jsp
-----------------------------------------------------------------------------------------------------------------------
That's reason why some investment banks (IB) had started to revise glove sector outlook.........
Hereby to enclose the latest glove preview & outlook by IB...
Macquarie downgrades Top Glove to 'underperform', halves target price as earnings could normalise in 2H21
(theedgemarkets.com / September 10, 2020 17:36 pm +08)
##https://www.theedgemarkets.com/article/macquarie-downgrades-top-glove-underperform-halves-target-price-earnings-could-normalise
JP Morgan pegs these glove makers' fair value at up to half their market price, says supernormal cycle is over
(theedgemarkets.com / December 12, 2020 00:16 am +08)
##https://www.theedgemarkets.com/article/jp-morgan-pegs-these-glove-makers-fair-value-half-their-market-price-says-supernormal-cycle
PublicInvest Research downgrades Top Glove to 'neutral' on ESG concerns
(theedgemarkets.com / December 18, 2020 10:38 am +08)
##https://www.theedgemarkets.com/article/publicinvest-research-downgrades-top-glove-neutral-esg-concerns
Revision :-
Macquarie - TP : 5.45
JP Morgan - TP : 3.50
PB IB - TP : 7.30
2020-12-30 08:43 | Report Abuse
OMG...Topglove suspended .............
2020-12-30 08:42 | Report Abuse
OMG...Topglove suspended .............
2020-12-30 08:42 | Report Abuse
OMG...Topglove suspended .............
2020-12-30 08:42 | Report Abuse
OMG...Topglove suspended .............
2020-12-30 08:41 | Report Abuse
OMG...Topglove suspended .............
2020-12-30 08:40 | Report Abuse
OMG...Topglove suspended .............
2020-12-30 08:40 | Report Abuse
Why suddenly suspended ??????????????????????
2020-12-29 20:40 | Report Abuse
Uncle also shareholder at PCCS...
Keyman188 still can recalled....Uncle last few months also holding Comfort & Ruberex...
What happened last few months!!!...
2020-12-29 20:31 | Report Abuse
Sooner or later...Uncle will say...
" I HAVE NO CHOICE, need to sell all due to margin call "...
Keyman188 always believe...History can't change but History will repeat again...
2020-12-29 17:20 | Report Abuse
Is it good news or bad news !!!...........
Just need some guidance from expertise or professional to guide this naive of Keyman188..............
Stock: [SUPERMX]: SUPERMAX CORPORATION BHD
2021-01-01 19:46 | Report Abuse
Keyman188 always like to repeat & repeat again...
Keyman188 not professional or expertise....
Keyman188 always spend more time listen to Professionals & Expertise to avoid burning Keyman188 hard earned money....
Do you feel very very strange !!!...............
Why expert only opt for Hartalega....but not Supermax !!!!!!!!!!
--------------------------------------------------------------------------------------------
The 11 stocks experts say you should own in 2021
(theedgemarkets.com / January 01, 2021 10:00 am +08)
The world went into real uncharted territories in 2020, starting with a pandemic no one had foreseen, and one the world had not experienced in decades. And while the subsequent slump in the equity markets was expected, the wild surge upwards as bulls dominated — including in Bursa Malaysia — was rather not, especially with the yet-to-dissipate shadows cast by the coronavirus.
Moving forward, the availability of vaccines raises optimism of a better year ahead.
The Edge contacted fund managers and analysts to tap their expertise in picking the stocks for 2021. Below is the list of stocks they highlighted:
Hartalega Holdings Bhd
If you still believe in the great earnings growth story in the rubber glove industry despite the availability of the Covid-19 vaccine, Hartalega Holdings Bhd could be a choice to buy on strength given that the stock has sagged almost 43% from its peak of RM21.16, according to Maybank IB.
Hartalega, the world’s largest nitrile glove maker, is one of Maybank IB’s top picks. It is projecting 580% growth on earnings per share in FY21 and 100% in FY22.
Hartalega stands out among the glove stocks, according to Maybank IB, due to lower oversupply risk in the nitrile space considering the limited supply of raw material, namely nitrile-butadiene rubber (NBR).
The anticipated continued robust growth has in turn made Hartalega appealing in terms of PER. Maybank IB noted that Hartalega's PER valuation is undemanding at nine times in 2021 and 12 times in 2022.
Furthermore, investment analysts believe that Hartalega may have room to raise its average selling prices to catch up with others in the industry that have already upped their selling prices substantially.
Any rebound might not be across the board in the coming year as the glove mania seems to be cooling off in the fourth quarter of 2020. Hence, stock selection is important moving forward.
## https://www.theedgemarkets.com/article/stock-picks